v3.26.1
Segment Information - Schedule of Significant Expense Categories Within Net Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Total research and development expenses $ 182,373 $ 126,095 $ 206,298
Tarcocimab program expenses      
Segment Reporting Information [Line Items]      
Total research and development expenses 54,049 39,496 90,513
KSI-501 and KSI-101 program expenses      
Segment Reporting Information [Line Items]      
Total research and development expenses 28,980 8,495 7,264
ABC Platform and other program expenses      
Segment Reporting Information [Line Items]      
Total research and development expenses 23,776 12,915 20,997
Payroll and personnel expenses      
Segment Reporting Information [Line Items]      
Total research and development expenses 56,082 45,522 65,382
Facilities and other research and development expenses      
Segment Reporting Information [Line Items]      
Total research and development expenses $ 19,486 $ 19,667 $ 22,142